Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease,
the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to
placebo.